181 related articles for article (PubMed ID: 10897004)
21. Comparison of platelet-lymphocyte ratio and CA 19-9 in differentiating benign from malignant head masses in patients with chronic pancreatitis.
Kakkat S; Rajan R; Sindhu RS; Natesh B; Raviram S
Indian J Gastroenterol; 2017 Jul; 36(4):263-267. PubMed ID: 28916969
[TBL] [Abstract][Full Text] [Related]
22. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker.
Frena A
Int J Biol Markers; 2001; 16(3):189-97. PubMed ID: 11605732
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
24. [Serum tissue polypeptide antigen in the differential diagnosis of chronic pancreatitis and exocrine pancreatic tumors. Preliminary results].
Ruibal A; Encabo G
Rev Esp Oncol; 1983; 30(3):313-6. PubMed ID: 6571374
[TBL] [Abstract][Full Text] [Related]
25. [Ca 19-9 in the diagnosis of pancreatic carcinoma].
Meggiato T; Basso D; Pasquali C; Angonese C; Bellinvia S; Del Favero G; Fabris C; Di Mario F; Plebani M; Pedrazzoli S
Minerva Med; 1989 May; 80(5):431-4. PubMed ID: 2747969
[TBL] [Abstract][Full Text] [Related]
26. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
27. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases.
Piantino P; Andriulli A; Gindro T; Pecchio F; Masoero G; Cavallini G; Naccarato R; Dobrilla G
Am J Gastroenterol; 1986 Jun; 81(6):436-9. PubMed ID: 3458359
[TBL] [Abstract][Full Text] [Related]
28. Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology.
Ferri MJ; Saez M; Figueras J; Fort E; Sabat M; López-Ben S; de Llorens R; Aleixandre RN; Peracaula R
PLoS One; 2016; 11(1):e0147214. PubMed ID: 26808421
[TBL] [Abstract][Full Text] [Related]
29. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
[TBL] [Abstract][Full Text] [Related]
30. Serological characteristics of autoimmune pancreatitis and its differential diagnosis from pancreatic cancer by using a combination of carbohydrate antigen 19-9, globulin, eosinophils and hemoglobin.
Yan T; Ke Y; Chen Y; Xu C; Yu C; Li Y
PLoS One; 2017; 12(4):e0174735. PubMed ID: 28369140
[TBL] [Abstract][Full Text] [Related]
31. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
[TBL] [Abstract][Full Text] [Related]
32. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil Gelatinase-Associated Lipocalin (NGAL) concentration in urine is superior to CA19-9 and Ca 125 in differentiation of pancreatic mass: Preliminary report.
Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
Cancer Biomark; 2016 Mar; 16(4):537-43. PubMed ID: 27002756
[TBL] [Abstract][Full Text] [Related]
34. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Bedi MM; Gandhi MD; Jacob G; Lekha V; Venugopal A; Ramesh H
Indian J Gastroenterol; 2009; 28(1):24-7. PubMed ID: 19529898
[TBL] [Abstract][Full Text] [Related]
35. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
36. [Value of the CA 19-9 tumor marker in differential diagnosis of space-occupying lesions in the head of the pancreas].
Böttger T; Hassdenteufel A; Boddin J; Küchle R; Junginger T; Prellwitz W
Chirurg; 1996 Oct; 67(10):1007-11. PubMed ID: 9011418
[TBL] [Abstract][Full Text] [Related]
37. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
38. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
Morris-Stiff G; Teli M; Jardine N; Puntis MC
Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
[TBL] [Abstract][Full Text] [Related]
39. [Tumoral markers and acute-phase reactants in the diagnosis of pancreatic cancer].
Irigoyen Oyarzabal AM; Amiguet García JA; López Vivanco G; Genollá Subirats J; Muñoz Villafranca MC; Ojembarrena Martínez E; Liso Irurzun P
Gastroenterol Hepatol; 2003 Dec; 26(10):624-9. PubMed ID: 14670235
[TBL] [Abstract][Full Text] [Related]
40. Tumour marker CA 50 levels compared to signs and symptoms in the diagnosis of pancreatic cancer.
Pålsson B; Masson P; Andrén-Sandberg A
Eur J Surg Oncol; 1997 Apr; 23(2):151-6. PubMed ID: 9158191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
